RESPIVERT LTD.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.respivert.com
Clinical Trials
13
Active:2
Completed:10
Trial Phases
2 Phases
Phase 1:7
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (77.8%)Phase 2
2 (22.2%)A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153
Phase 1
Terminated
- Conditions
- AsthmaHealthy Volunteers
- Interventions
- Drug: RV6153 14 day repeat doseDrug: RV6153 single doseDrug: RV6153 28 day repeat doseDrug: RV6153 matching placebo single doseDrug: RV6153 matching placebo 14 day repeat doseDrug: RV6153 matching placebo 28 day repeat dose
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 55
- Registration Number
- NCT02517359
Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers
Completed
- Conditions
- AsthmaCOPD
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 25
- Registration Number
- NCT02490358
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: RV1729 28 day repeat doseDrug: RV1729 matching placebo 28 day repeat dose
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT02140346
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days
Phase 1
Completed
- Conditions
- Healthy VolunteersAsthma
- Interventions
- Drug: RV1729 28 day repeat doseDrug: RV1729 14 day repeat doseDrug: RV1729 single doseDrug: RV1729 matching placebo 28 day repeat doseDrug: RV1729 matching placebo 14 day repeat doseDrug: RV1729 matching placebo single dose
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 49
- Registration Number
- NCT02140320
Safety, Tolerability and Pharmacokinetics (PK) of RV1162 in Healthy Subjects and COPD Patients
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)Healthy Volunteers
- Interventions
- Drug: RV1162 single doseDrug: RV1162 matching placebo single dose
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2014-11-20
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 78
- Registration Number
- NCT01970618
- Prev
- 1
- 2
- 3
- Next
News
No news found